Subscribe
Pet Tech
8 min read

Kai Micah Mills | Founder, Cryopets

Cryopets founder and Thiel Fellow Kai Micah Mills on vitrifying pets after death, the science behind cryopreservation and revival, why 6,000 people have joined the waitlist, and why the first step toward radically extended life may start with the animals we love most.

Written by
Roy Ben-Tzvi
Published on
October 27, 2026
Kai Micah Mills, Founder of Cryopets

Cryonics has long lived on the fringe — dismissed as science fiction or Silicon Valley fantasy. But a new generation of founders is treating it as an engineering problem.

Kai Micah Mills, founder of Cryopets and Thiel Fellow, is building a company designed to preserve pets in a vitrified state immediately after death, with the long-term goal of revival once medicine advances far enough.

Behind the polarizing headlines is real scientific progress, serious capital, and a growing customer base that looks far more mainstream than most people would expect. In this conversation, Micah explains the breakthroughs already happening in cryopreservation, why thousands of pet owners have joined the waitlist, and why he believes the first practical step toward radically extended life may not begin with humans — but with the animals we love most.

‍

You dropped out of high school, started building Minecraft servers, and sold your first company for six figures at just 16. What did those early experiences teach you about building companies and taking risks at such a young age?

Dropping out of high school is the single best decision I have made in my life. Minecraft was the launchpad that taught me how to be an entrepreneur. I was able to experience managing dozens of employees, thousands of customers, and large amounts of money while my peers were still in high school. Beyond just learning how to bootstrap and operate companies from scratch, I learned that isolation will force you to discover who you truly are, school is a scam, and to always, always, bet on yourself.

Subscribe to newsletter

Join our newsletter to stay up to date on features and releases.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

By clicking Sign Up you're confirming that you agree with our Terms and Conditions.

Pro
Keep Reading

Other Interviews

More conversations with founders, operators, and investors building the future of pet care.

Learn more
Deven Vespi | Advisor, DRV Advisory
Pet Health & Wellness
13 min read

Deven Vespi | Advisor, DRV Advisory

Clinically proven has no shared definition in pet, yet it now shapes deals as much as labels. Deven Vespi learned the trade in FDA-regulated animal health, and she explains how to check a study before you trust it or build a deal on it. She covers sample sizes, dosing gaps, why brands get blindsided by their own research, and how long published data stays an edge.

Learn more
Learn more
Meet the Founders: 3 Startups Shaping the Future of Pet Health
Pet Health & Wellness
10 min read

Meet the Founders: 3 Startups Shaping the Future of Pet Health

Pawsible Ventures took seven of more than 130 applicants into its second cohort. Three of them work very different corners of pet health. Nicole Shlomof and Gila Leibovitch of Pawp Water sell functional water to owners who already fill the bowl, Andria Beal of EpiPaws turned dolphin epigenetics research into biological-age tests for dogs and cats, and Elliot Greenwood of ChckVet sells software to vet practices that resist new tech.

Learn more
Learn more
Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics
Pet Health & Wellness
17 min read

Elizabeth Iorns | Co-Founder & CEO, Familiar Therapeutics

Elizabeth Iorns lost her French Bulldog to a brain tumor that a published canine study suggested could be treated, but no company had taken the drug forward for dogs. Now she and Science Exchange co-founder Dan Knox license the companion animal rights to human drugs at Familiar Therapeutics: 13 programs and $5 million raised in five months, plus a pitch to pharma that pet trials validate targets faster than phase two.

Learn more
View all interviews